Buradasınız

Anasayfa » Content

Kan ve dışkı örneklerinden izole edilen Salmonella ve Shigella izolatlarının antibiyotik dirençleri

Antimicrobial resistance of Salmonella and Shigella spp. isolated from blood and feces samples

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The present study was performed to contribute to the constitution of treatment protocols and to the follow up of future resistance development by determining antibiotic susceptibilities, the presence of extended spectrum beta lactamase and antimicrobial resistance rates in 21 Salmonella and 31 Shigella spp. isolated from feces samples and 30 Salmonella spp. isolated from blood samples at our bacteriology laboratory between 2001 and 2004. Antimicrobial susceptibilities were determined by using Kirby-Bauer disc diffusion method according to the criteria of Clinical and Laboratory Standards Instute, 2005. Resistance rates in Shigella isolates for trimethoprim/sulphamethoxazole and tetracycline were 71% and for amoxycillin/clavulanic acid was 9.7%. In Salmonella isolates from feces samples, resistance rates for ceftazidime, cefotaxime, trimethoprim/sulphamethoxazole and gentamicin were 4.8%, 9.5% for amoxycillin/clavulanic acid, and 33.3% for tetracycline. In Salmonella isolates from blood samples resistance rates were 50.0% for ampicillin, 20.0% for nalidixic acid, 10.0% for amoxycillin/clavulanic acid, and 6.7% for chloramphenicol, cefotaxime, trimethoprim/sulphamethoxazole, and 3.3% for gentamicin, tetracycline, ceftazidime, and piperasillin-tazobactam. There was no extended spectrum beta lactamase in isolates studied. Although there was no resistance for kinolons that have been frequently used instead of other antibiotics in treatment protocols recently, a clinical treatment failure risk should be kept in mind considering the resistance rate of 20.0% for nalidixic acid.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışma, bakteriyoloji laboratuvarımızda 2001 ile 2004 yılları arasında dışkı örneklerinden izole edilen 21 Salmonella ve 31 Shigella izolatı ile kan örneklerinden izole edilen 30 Salmonella izolatının antibiyotik duyarlılıklarıyla, geniş spektrumlu beta laktamaz pozitifliklerinin saptanıp direnç paternlerinin belirlenerek tedavi protokollerine ve gelecekteki direnç gelişimlerinin izlenmesine katkıda bulunulması amacıyla yapılmıştır. Antibiyotik duyarlılıkları 2005 "Clinical and Laboratory Standards Institute" kriterlerine göre Kirby-Bauer disk difüzyon test yöntemiyle belirlenmiştir. Shigella izolatlarında trimetoprim-sülfametoksazol ve tetrasikline %71, amoksisilin-klavulanik aside %9.7 oranında direnç gözlenmiştir. Dışkı örneklerinden izole edilen Salmonella izolatlarında seftazidim, sefotaksim, trimetoprim-sülfametoksazol ve gentamisine %4.8, amoksisilin-klavulanik aside %9.5, tetrasikline %33.3 direnç belirlenmiştir. Kan örneklerinden izole edilen Salmonella izolatlarında ampisiline %50, nalidiksik aside %20, amoksisilinklavulanik aside %10, kloramfenikol, sefotaksim, trimetoprim-sülfametoksazole %6.7, gentamisin, tetrasiklin, seftazidim ve piperasilin-tazobaktama %3.3 direnç saptanmıştır. İzolatlarda geniş spektrumlu beta laktamaz pozitifliği belirlenmemiştir. Tedavi protokollerinde son yıllarda sıklıkla diğer ilaçların yerini alan kinolonlara direnç gözlenmemiş olmakla birlikte, %20 olarak belirlenen nalidiksik asid direnç oranı göz önüne alındığında, klinik başarısızlıkla karşılaşma olasılığı nedeniyle tedavi yaklaşımlarında bu durumun göz ardı edilmemesi gerektiği ortaya çıkmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-kan-diski-orneklerinden-izole-edilen-salmonella-shigella-izolatlarinin-antibiyotik-direncleri.pdf
  • 3
141-146
  • Turkish

REFERENCES

References: 

1. Clinical and Laboratory Standards Institute. Performance
Standards for Antimicrobial Disk Susceptibility Tests.
Fifteenth Informational Supplement. CLSI Document
M100-S15. Wayne, Pa: Clinical and Laboratory Standarts
Institute, 2005.
2. Lyon DJ, Scheel O, Adeyemi-Doro FA, Ling TK, Cheng
AF, Norrby SR. Antimicrobial susceptibility and extended-spectrum beta-lactamases of Hong Kong isolates of
Enterobacteriaceae. Scand J Infect Dis 1996; Suppl 101:
17-20.
3. Winokur PL, Canton R, Casellas JM, Legakis N.
Variations in the prevalence of strains expressing an
extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the
Western Pacific region. Clin Infect Dis 2001; 32 (Suppl
2): 94-103.
4. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A,
Fadda G. The Italian ESBL Study Group. Occurrence of
extended-spectrum beta-lactamases in members of the
family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.
Antimicrob Agents Chemother 2002; 46: 196-202.
5. Wong-Beringer A. Therapeutic challenges associated with
extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy
2001; 21: 583-592.
6. Bopp CA, Brenner FW, Fields PI, Wells JG, Strockbine
NA. Escherichia, Shigella, and Salmonella. In: Murray
PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH
(eds). Manual of Clinical Microbiology. 8th ed.
Washington D.C.: ASM Pres, 2003: 654-671.
7. Merino LA, Hrenuk GE, Ronconi MC, Alonso JM.
Antibiotic resistance and molecular epidemiology of
Shigella spp. in northeastern Argentina. Rev Panam Salud
Publica 2004; 15: 219-224.
8. Haznedaroðlu T, Baysallar M, Küçükkaraarslan A, Gün
H. Akut diareli olgulardan izole edilen Shigella türlerinin
daðýlýmý ve çeþitli antibiyotiklere karþý duyarlýlýklarý.
Gaziantep Üniversitesi Týp Fakültesi Dergisi 1993; 4:
172-180.
9. Panhotra BR, Saxena AK, Al-Ghamdi AM. Emerging
nalidixic acid and ciprofloxacin resistance in nontyphoidal Salmonella isolated from patients having acute
diarrhoeal disease. Ann Saudi Med 2004; 24: 332-336.
10. Wybot I, Wildemauwe C, Godard C, Bertrand S, Collard
JM. Antimicrobial drug resistance in nontyphoid human
Salmonella in Belgium: trends for the period 2000-2002.
Acta Clin Belg 2004; 59: 152-160.
11. Urbarlý A, Özgenç O, Ýnan N, Erdenizmenli M, Oran E.
Salmonella ve Shigella bakterilerinin in vitro olarak bazý
antibiyotiklere duyarlýlýklarýnýn araþtýrýlmasý. SSK Ýzmir
Eðitim Hastanesi Týp Dergisi 1997; 3: 45-47.
12. Özgüneþ N, Üçýþýk AC, Yazýcý S, Ceylan N, Gündeþ S,
Ceylan T. 1992-1993 yýllarýnda SSK Göztepe Eðitim
Hastanesi Klinik Mikrobiyoloji Laboratuvarýnda izole
edilen Salmonella, Shigella suþlarý ve anitibiyotik
duyarlýlýklarý. Göztepe Týp Dergisi 1995; 10: 208-210.
13. Sümerkan B, Ýnan M, Çaðlayangil A, Aygen B, Doðanay
M. Klinik örneklerden izole edilen Salmonella'larýn in
vitro antibiyotik duyarlýlýklarýnýn deðerlendirilmesi.
Mikrobiyoloji Bülteni 1994; 28: 21-26.
14. Kilic D, Tulek N, Tuncer G, Doganci L, Willke A.
Antimicrobial susceptibilities and ESBL production rates
of Salmonella and Shigella strains in Turkey. Clin
Microbiol Infect 2001; 7: 341-342.
15. Otkun M, Erdem B, Akata F, et al. Antibiotic resistance
patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur J Clin Microbiol Infect Dis
2001; 20: 206-209.
16. Baysallar M, Küçükkaraarslan A, Albay A, Baþustaoðlu
AC, Gün H. Dýþký ve kan örneklerinden izole edilen
Salmonella serotiplerinin insidansý ve çoklu antibiyotik
direnci. Klimik Dergisi 1995; 8: 32-35.
17. Levy SB, Marshall B. Antibacterial resistance worldwide:
causes, challenges and responses. Nat Med 2004; 10: 122-
129.
18. Wagenlehner FM, Weidner W, Naber KG. Emergence of
antibiotic resistance amongst hospital-acquired urinary
tract infections and pharmacokinetic/pharmacodynamic
considerations. J Hosp Infect 2005; 60: 191-200.
19. Andersson DI. Persistence of antibiotic resistant bacteria.
Curr Opin Microbiol 2003; 6: 452-456.
20. Chiew YF, Yeo SF, Hall LM, Livermore DM. Can susceptibility to an antimicrobial be restored by halting its
use? The case of streptomycin versus Enterobacteriaceae.
J Antimicrob Chemother 1998; 41: 247-251.
21. Kariuki S, Gilks CF, Kimari J, Muyodi J, Waiyaki P, Hart
CA. Plasmid diversity of multi-drug-resistant Escherichia
coli isolated from children with diarrhoea in a poultryfarming area in Kenya. Ann Trop Med Parasitol 1997; 91:
87-94.
22. Gülay Z. Gram negatif çomaklarda antibiyotik direnci:
2003-2004 Türkiye haritasý. Ankem Dergisi 2005; 19 (Ek
2): 66-77.
23. Szych J, Cieslik A, Paciorek J, Kaluzewski S. Multidrug
resistance to antibacterial drugs of Salmonella enterica
subsp. enterica strains isolated in Poland in the 1998-1999
period. Med Dosw Mikrobiol 2001; 53: 17-29.
24. Szych J, Cieslik A, Paciorek J, Kaluzewski S. Antibiotic
resistance in Salmonella enterica subsp. enterica strains
isolated in Poland from 1998 to 1999. Int J Antimicrob
Agents 2001; 18: 37-42.
25. Baraniak A, Sadowy E, Hryniewicz W, Gniadkowski M.
Two different extended-spectrum beta-lactamases
(ESBLs) in one of the first ESBL-producing Salmonella
isolates in Poland. J Clin Microbiol 2002; 40: 1095-1097.
26. Vahaboðlu MH, Mülazýmoðlu L, Dodanlý S ve ark. Çoðul
antibiyotik dirençli geniþletilmiþ spektrumlu beta-laktamaz yapan Salmonella paratyphi B suþlarý. Klimik Dergisi
1993; 6: 9-12.

Thank you for copying data from http://www.arastirmax.com